RP-A501: Audience

RP-A501 is a gene therapy being developed by Rocket Pharmaceuticals for the treatment of Danon Disease, a rare genetic disorder that affects heart muscle function. This therapy aims to address the underlying genetic causes of the disease, offering hope for improved patient outcomes.